Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.

Levels of HdmX Expression Dictate the Sensitivity of Normal and Transformed Cells to Nutlin-3

Open access

Abstract

Hdm2 and HdmX coordinately regulate the stability and function of p53. Each is overexpressed in subsets of many different types of malignancy, and most of these subsets maintain wild-type p53. Nutlins, newly discovered small-molecule inhibitors of the Hdm2-p53 interaction, offer a novel strategy for therapy of tumors with wild-type p53. We now show that Nutlin-3 efficiently induces apoptosis and diminishes long-term survival of human fibroblasts transformed in vitro by Hdm2 but not HdmX. The resistance of cells overexpressing HdmX to Nutlin-3 is due to its inability to disrupt the p53-HdmX interaction, resulting in continued suppression of p53 activity. Although HdmX overexpression yielded cells resistant to Nutlin-3, ablation of HdmX expression by short hairpin RNA sensitized tumor cells to Nutlin-3–mediated cell death or arrest. Furthermore, deletion of the COOH-terminal RING finger domain of HdmX completely reversed the resistance to Nutlin-3, probably reflecting the requirement of the RING finger for interaction with Hdm2. Thus, the relative abundance of Hdm2 and HdmX and the specificity of Nutlin-3 for Hdm2 influence the sensitivity of cells to p53-dependent apoptosis or arrest in response to Nutlin-3. Our findings establish Hdm2 and HdmX as independent therapeutic targets with respect to reactivating wild-type p53 as a means for cancer therapy. (Cancer Res 2006; 66(6): 3169-76)

Overview

Integrity signals

Registry

Crossref · 10.1158/0008-5472.can-05-3832

Cites

46 of 46 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 46 references

Cited by

See all 189

Metadata

Authors
Patton, J. T., Mayo, L. D., Singhi, A. D., Gudkov, A. V., Stark, G. R., & Jackson, M. W.
Affiliations
  • Cleveland Clinic (US)
  • Case Comprehensive Cancer Center (US)
Venue
Cancer Research
Published
2006-03-15
Volume
66
Issue
6
Pages
3169-3176
ISSN
  • 0008-5472 (ISSN-L)
  • 1538-7445
OpenAlex
W2106718280
Cited by
189
References
46
Citations by year
2026: 3 · 2025: 3 · 2024: 1 · 2023: 7 · 2022: 5 · 2021: 5 · 2020: 5 · 2019: 2 · 2018: 6 · 2017: 7 · 2016: 9 · 2015: 9 · 2014: 9 · 2013: 13 · 2012: 14
FWCI
10.61
Type
journal article
Language
en
Open access
Locations
  • Cancer Research (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Case Comprehensive Cancer Center, Case Western Reserve University (P30CA43703)
  • National Heart, Lung, and Blood Institute (F32HL072661)
  • National Cancer Institute (P-30 CA43703, R01CA109262, P30CA043703)
  • National Institute of General Medical Sciences (R01GM049345)
Topics
  • Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Heat shock proteins research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
Keywords
HDMX, MDM2, Nutlin-3, p53, p53-MDM2 interaction, p53 reactivation, apoptosis, RING domain, shRNA, transformed fibroblasts, drug resistance, cancer therapy
MeSH terms
Antineoplastic Combined Chemotherapy Protocols, Cell Transformation, Neoplastic, Colonic Neoplasms, Doxorubicin, Drug Screening Assays, Antitumor, Drug Synergism, Fibroblasts, Humans, Imidazoles, Nuclear Proteins, Piperazines, Proto-Oncogene Proteins, Tumor Suppressor Protein p53, Protein Structure, Tertiary, Cell Cycle Proteins, RNA, Small Interfering, HCT116 Cells, Proto-Oncogene Proteins c-mdm2

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Levels of HdmX Expression Dictate the Sensitivity of Normal and Transformed Cells to Nutlin-3. https://app.cochat.ai/papers/10.1158/0008-5472.can-05-3832
The paper
Patton, J. T., Mayo, L. D., Singhi, A. D., Gudkov, A. V., Stark, G. R., & Jackson, M. W. (2006). Levels of HdmX Expression Dictate the Sensitivity of Normal and Transformed Cells to Nutlin-3. Cancer Research. https://doi.org/10.1158/0008-5472.can-05-3832

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.